Clone yts 169

Manufactured by BioXCell

The Clone YTS 169.4 is a laboratory equipment product. It is a cell line used for research purposes.

Automatically generated - may contain errors

Lab products found in correlation

Control liposome, by Formumax Scientific (1 mentions) Clodronate liposome, by Formumax Scientific (1 mentions) Clone rmp1 14, by BioXCell (1 mentions) Clone pk136, by BioXCell (1 mentions) Clone gk1, by BioXCell (1 mentions) Ltf 2, by BioXCell (1 mentions) Clone ltf 2, by BioXCell (1 mentions) Clone 10f 9g2, by BioXCell (1 mentions) Non specific rat igg2b clone ltf 2, by BioXCell (1 mentions)

Spelling variants of this product

YTS 169.4 (35 citations) CD8 (clone YTS 169.4, (8 citations) CD8 depletion antibody (Clone YTS 169.4, (5 citations) Anti-mouse CD8α (Clone YTS 169.4, (4 citations) CD8 mAb (clone YTS 169.4), (3 citations) Anti-mouse CD8 (clone YTS 169.4; (2 citations) Anti-CD8 (clone YTS 169 (2 citations) Anti-CD8α (Clone YTS 169.4, (2 citations)

7 protocols using clone yts 169

Murine Pancreatic Tumor Modeling

Check if the same lab product or an alternative is used in the 5 most similar protocols

All human PDAC tissues were obtained from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The protocols using human specimens were approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (ID: 2021-194).
For the studies involving animals, appropriate permission was given from the Animal Experimental Ethical Inspection of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (20180509). A sample of 6-week-old female C57BL/6 mice were injected subcutaneously with 5 × 10⁵ Panc02 cells or 3 × 10⁵ KPC cells (mouse pancreatic cancer cell lines) on day 0. For macrophage-depletion studies, mice were intraperitoneally injected with clodronate liposomes or control liposomes (FormuMax Scientific, Sunnyvale, CA, USA) at 200 μL per mouse on days -1 and 0, and every 3 days afterward until the completion of the study. In the T-cell-depletion experiment, an antibody (Ab) to deplete CD8⁺ cells (clone YTS 169.4; BioXCell) was injected intraperitoneally at 200 µg per mouse on days -1 and 0, and every 5 days afterward until the end of the study. The tumor volume was calculated as width² × length/2. On day 20, all mice were sacrificed, and tumor tissues were collected for further analysis.

Yang X., Lin J., Wang G, & Xu D. (2022). Targeting Proliferating Tumor-Infiltrating Macrophages Facilitates Spatial Redistribution of CD8+ T Cells in Pancreatic Cancer. Cancers, 14(6), 1474.

+ Open protocol

+ Expand

CD8 Depletion in Vaccinated Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

At least 4 weeks after vaccination, mice were intraperitoneally injected with three doses of 20 µg of rat monoclonal anti-CD8 antibody (BioXCell, clone YTS169.4, ref BE0117) in consecutive days.

Menares E., Gálvez-Cancino F., Cáceres-Morgado P., Ghorani E., López E., Díaz X., Saavedra-Almarza J., Figueroa D.A., Roa E., Quezada S.A, & Lladser A. (2019). Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells. Nature Communications, 10, 4401.

+ Open protocol

+ Expand

Depletion of Immune Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the in vivo depletion of CD4⁺ T, CD8⁺ T, or NK cells, anti-CD8 antibody (400 μg; clone YTS 169.4, BioXcell), anti-CD4 antibody (400 μg; clone GK1.5, BioXcell), or anti-NK1.1 antibody (400 μg; clone PK136, BioXcell) was administered twice weekly via intraperitoneal injection into MC38 tumor–bearing C57BL/6 mice 1 day before the first treatment with anti–PD-1 antibody (clone RMP1-14, BioXcell; 5 doses of 200 μg every 3 days).

Zhou H., Wang Y., Xu H., Shen X., Zhang T., Zhou X., Zeng Y., Li K., Zhang L., Zhu H., Yang X., Li N., Yang Z, & Liu Z. (2022). Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy. The Journal of Clinical Investigation, 132(16), e161065.

+ Open protocol

+ Expand

Evaluation of Anti-PD-L1 Therapy in Murine Tumor Models

Check if the same lab product or an alternative is used in the 5 most similar protocols

Note that 1 × 10⁶ B16F10 or LLC cells were resuspended in Hank’s Balanced Salt Solution (Gibco, #14170112) and subcutaneously injected into the right flank of 6- to 8-week-old female C57BL/6 mice. Anti–PD-L1 (Bio X Cell, clone 10F.9G2, #BE0101, 100 μg/mouse) mAbs and IgG isotype control antibodies (BioX Cell, clone LTF-2, #BE0090, 100 μg/mouse) were administered on days 6, 9, and 12. For the drug combination experiment, mice were treated with swainsonine (APExBIO, #B7316) by oral gavage daily in 1 mg/kg/day from day 6 for 2 weeks. For CD8 depletion studies, anti-CD8 (Bio X Cell, clone YTS 169.4, #BE0117,150 μg/mouse) was administered 1 day prior to treatment and then every 3 days for a total of 3 doses. Tumors were measured every 3 days beginning on day 6 after tumor challenge until the survival endpoint was reached. Measurements were assessed manually by assessing the longest dimension (length) and the longest perpendicular dimension (width). Tumor volume was calculated using the formula 1/2 × length × width². All mouse experiments were carried out at the Shanghai Model Organisms Center. The mouse experiments were approved by the Institutional Animal Care and Use Committee of the Institute of Biochemistry and Cell Biology and performed in accordance with this committee’s guidelines.

Shi S., Gu S., Han T., Zhang W., Huang L., Li Z., Pan D., Fu J., Ge J., Brown M., Zhang P., Jiang P., Wucherpfennig K.W, & Liu X.S. (2020). Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(22), 5990-6002.

+ Open protocol

+ Expand

Tumor Immunotherapy Depletion and Monitoring

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tumor cells (1 × 10⁶ LLC, 5 × 10⁵ CT26, 5 × 10⁵ 4T1, 5 × 10⁵ MC38, or 5 × 10⁵ MC38-OVA) were suspended in 100 µL of phosphate-buffered saline (PBS). Then, the tumor cells were inoculated subcutaneously into the right flanks of the mice on day 0. Anti-CD8a antibody (200 µg; clone YTS169.4, Bio X Cell) or control IgG2b (200 µg; clone LTF-2, Bio X Cell) was injected intraperitoneally to deplete CD8⁺ T cells on days 0, 3, 6, 9, and 12 post-tumor challenge. Anti-PD-L1 (200 µg; clone 10 F.9G2™, Bio X Cell) or IgG2b control (200 µg; clone LTF-2, Bio X Cell) were injected intraperitoneally on days 4, 7, 10, and 13 post-tumor challenge. Tumor growth was monitored every other day, and the tumor volumes were calculated using the formula: V = (length × width²)/2. Mice were sacrificed using cervical spinal cord dislocation at specified time points post-tumor inoculation, and tumor tissues, tumor-draining lymph nodes (TDLNs), and non-draining lymph nodes (NDLNs) were dissociated into single cells for flow cytometry analysis. All experimental procedures were adhered to the Institutional Animal Care and Use Committee of TMMU guidelines.

Hou J., Xie S., Gao J., Jiang T., Zhu E., Yang X., Jin Z., Long H., Zhang A., Yang F., Wang L., Zha H., Jia Q., Zhu B, & Wang X. (2024). NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice. Experimental Hematology & Oncology, 13, 48.

+ Open protocol

+ Expand

4T1 Breast Cancer Xenograft Model with Immunotherapy

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mouse breast cancer cell line, 4T1, was used to generate orthotopic xenograft in BALB/c mice. The 4T1 cell line was authenticated by short tandem repeat (STR) profiling and tested for any microbial or bacterial contamination before using in mice. The 4T1 cells (10,000/mouse) were implanted orthotopically in mammary fat pads of female Balb/c mice (10–12 weeks). The tumor-bearing mice with average tumor diameter of 5 mm were randomized into five groups and treated as follow: group 1—control; group 2—isotype control (first two dose 100 µg/mouse; next two dose of 50 µg/mouse); group 3—anti-mouse CD70 mAb (first two dose 100 µg/mouse; next two dose of 50 µg/mouse), group 4—URMC-099 (dose 7.5 mg/kg body weight daily) and group 5—URMC-099 (dose 7.5 mg/kg body weight daily) and anti-mouse CD70 mAb (first two dose 100 µg/mouse; next two dose of 50 µg/mouse). All treated and control mice were sacrificed on day 14. To deplete CD8⁺ T cells in tumor-bearing mice, anti-CD8 antibody (10 mg/kg, clone YTS 169.4, Bio X Cell) was administered,26 (link) 1 day prior to treatment with URMC-099. The second and third dose of anti-CD8 antibody was given on day 6 and day 11 from first day of URMC-099 administration. The serum and organs were used for enzyme-linked immunosorbent assay (ELISA), flow cytometry and immunohistochemistry (IHC) analyses.

Kumar S., Singh S.K., Viswakarma N., Sondarva G., Nair R.S., Sethupathi P., Dorman M., Sinha S.C., Hoskins K., Thatcher G., Rana B, & Rana A. (2020). Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8+ T cells. Journal for Immunotherapy of Cancer, 8(2), e000494.

+ Open protocol

+ Expand

In vivo T cell depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols

A rat monoclonal antibody recognizing mouse CD8 T cells (clone YTS 169.4, BioXCell, Inc.) or CD4 T cells (clone GK1.5, BioXCell, Inc.) was administered i.p. at 200 μg/dose. Control mice received equivalent amounts of nonspecific rat IgG2b (clone LTF-2, BioXCell, Inc.). Antibody was administered on days -1, 3, 6, 10, and 13 relative to infection (day 0).

Molloy C.T., Andonian J.S., Seltzer H.M., Procario M.C., Watson ME J.r, & Weinberg J.B. (2017). Contributions of CD8 T Cells to the Pathogenesis of Mouse Adenovirus Type 1 Respiratory Infection. Virology, 507, 64-74.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!